Subscribe to RSS
DOI: 10.1055/s-2002-36128
Bedeutung der pulmonalen Lymphknotenmetastasierung bei lokal fortgeschrittenen, nicht-kleinzelligen Bronchialkarzinomen
Significance of Pulmonary Lymph Node Metastases in Locally Advanced Non-Small Cell Lung Cancer Diese Studie wurde der Ruhrlandklinik zu ihrem 100-jährigen Jubiläum gewidmet.DanksagungDie Autoren bedanken sich bei Frau Barbara Daut für ihre wertvolle Mitarbeit in der Sammlung und Bearbeitung der Patientendaten.Publication History
Publication Date:
12 December 2002 (online)
![](https://www.thieme-connect.de/media/pneumologie/200212/lookinside/thumbnails/10.1055-s-2002-36128-1.jpg)
Zusammenfassung
Hintergrund: Das lokal fortgeschrittene (T3 - 4) nicht-kleinzellige Bronchialkarzinom mit pulmonalen Lymphknotenmetastasen (N1) beinhaltet unterschiedliche Tumormanifestationen, die verschiedenen lymphatischen Metastasierungsmustern und möglicherweise Prognosen entsprechen. Patienten und Methode: Retrospektiv wurden die Krankenblätter und Verlaufsunterlagen der 181 Patienten mit pathologischem Tumorstadium IIIA-pT3N1 und IIIB-pT4N1 erfasst, die im Zeitraum 1990 - 1995 operiert wurden. Der Altersmedian betrug 62 Jahre (Bereich: 34 - 80 Jahre). Ergebnisse: Nach 188 resektiven Eingriffen betrug die 30-Tage-Letalität 3,7 %. Die folgende Analyse betrifft die 181 überlebenden Patienten, wobei 110 (60,8 %) Pneumonektomien und 71 (39,2 %) Lobektomien/Bilobektomien durchgeführt wurden. Das pathologische Stadium nach der UICC-Klassifikation 1997 lautete T3N1 in 128 (70,7 %) und T4N1 in 53 (29,3 %). Ein metastatischer Befall der hilären, interlobären und lobären Lymphknoten wurde in 44 (24,3 %), 17 (9,4 %) bzw. 27 (14,9 %) Patienten nachgewiesen, eine direkte Lymphknoteninfiltration in 93 Patienten (51,4 %). Die 3-, 5- und 10-Jahres-Überlebensraten nach Kaplan-Meier betrugen für N1 hilär 23 %, 13 % und 8 %, für N1 interlobär 18 %, 6 % und 0 %, für N1 lobär 48 %, 37 % und 22 %, und für N1 direkt 32 %, 27 % und 21 %. Der Befall der hilären Lymphknoten korrelierte mit einer eindeutig ungünstigeren Prognose (p = .0366). Schlussfolgerungen: Die metastatische Absiedlung in hiläre Lymphknoten bei lokal fortgeschrittenem NSCLC kann prognostisch als initiale N2-Erkrankung betrachtet werden und erfordert eine entsprechende Behandlung. Die direkte Infiltration der pulmonalen Lymphknoten erscheint prognostisch weniger ungünstig für die betroffenen Patienten.
Abstract
Background. The locally advanced (T3 - 4) non-small cell lung cancer with pulmonary lymph node metastases (N1) is a mixture of different subgroups of disease with varying pattern of tumor extension and long-term survival rates. Patients and methods: We retrospectively reviewed hospital records and follow-up data of 181 patients operated on between 1990 and 1995 with pathological stage IIIA-pT3N1 and IIIB-pT4N1. Median age was 62 years (range 34 - 80). Results: The operative mortality was 3.7 %. The analysis was carried out on the 181 hospital survivors. The operative procedure was a pneumonectomy in 110 cases (60.8 %) and a lobectomy/bilobectomy in 71 (39.26 %). The pathological stage according to the UICC TNM-Classification of 1997 was T3N1 in 128 (70.7 %) and T4N1 in 53 (29.3 %). We observed a metastatic involvement of the hilar, interlobar and lobar lymph nodes in 44 (24.3 %), 17 (9.4 %), and 27 (14.9 %) patients, respectively, whereas a direct infiltration in 93 patients (51.4 %). The actuarial overall 3-, 5- and 10-year survival rates for N1 hilar was 23 %, 13 % and 8 %, for N1 interlobar was 18 %, 6 % and 0 %, for N1 lobar was 48 %, 37 % and 22 %, and for N1 direct was 32 %, 27 % and 21 %, respectively. The involvement of hilar lymph nodes correlates with a worse prognosis (p = .0366). Conclusions: Metastases to the hilar lymph nodes in locally advanced NSCLC can be considered an initial N2-disease and should be treated correspondingly. Lymph node involvement by direct invasion is associated with a relatively more favourable prognosis for the patients.
Literatur
- 1 PORT Meta-analysis Trialists Group . Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet. 1998; 352 257-263
- 2 Mountain C F. Revisions in the International System for staging lung cancer. Chest. 1997; 111 1710-1717
- 3 Fujimoto T, Zaboura G, Fechner S. et al . Completion pneumonectomy: Current indications, complications, and results. J Thorac Cardiovasc Surg. 2001; 121 484-490
- 4 World Health Organization .International histological classification of tumours. Geneva: World Health Organization 1969 - 1981; 2nd ed. Berlin: Springer-Verlag 1988-Present
- 5 Mountain C F, Dresler C M. Regional lymph node classification for lung cancer staging. Chest. 1997; 111 1718-1723
- 6 Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53 457-481
- 7 Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966; 50 163-170
- 8 Cox D R. Regression models and life tables. J R Stat Soc B. 1972; 34 187-220
- 9 Yano T, Yokoyama H, Inoue T. et al . Surgical results and prognostic factors of pathologic N1 disease in non-small-cell carcinoma of the lung. Significance of N1 level: lobar or hilar nodes. J Thorac Cardiovasc Surg. 1994; 107 1398-1402
- 10 van Velzen E, Snijder R J, Brutel de la Riviere A. et al . Type of lymph node involvement influences survival rates in T1N1M0 non-small cell lung carcinoma. Lymph node involvement by direct extension compared with lobar and hilar node metastases. Chest. 1996; 110 1469-1473
- 11 van Velzen E, Snijder R J, Brutel de la Riviere A. et al . Lymph node type as a prognostic factor for survival in T2 N1 M0 non-small cell lung carcinoma. Ann Thorac Surg. 1997; 63 1436-1440
- 12 van Velzen E, Brutel de la Riviere A, Elbers H J. et al . Type of lymph node involvement and survival in pathologic N1 stage III non-small cell lung carcinoma. Ann Thorac Surg. 1999; 67 903-907
- 13 Asamura H, Suzuki K, Kondo H. et al . Where is the boundary between N1 and N2 stations in lung cancer?. Ann Thorac Surg. 2000; 70 1839-1845 discussion. 1845-1846
- 14 Maggi G, Casadio C, Mancuso M. et al . Resection and radical lymphadenectomy for lung cancer: prognostic significance of lymphatic metastases. Int Surg. 1990; 75 17-21
- 15 Martini N, Burt M E, Bains M S. et al . Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg. 1992; 54 460-465 discussion. 466
- 16 Riquet M, Manac'h D, Le Pimpec-Barthes F. et al . Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung. Ann Thorac Surg. 1999; 67 1572-1576
- 17 Yoshino I, Nakanishi R, Osaki T. et al . Unfavorable prognosis of patients with stage II non-small cell lung cancer associated with macroscopic nodal metastases. Chest. 1999; 116 144-149
- 18 Naruke T, Goya T, Tsuchiya R. et al . Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg. 1988; 96 440-447
- 19 Marra A, Hillejan L, Zaboura G. et al .Pathologic N1 non-small cell lung cancer: Correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg 2002 [in press]
- 20 Ferguson M K, Little A G, Golomb H M. et al . The role of adjuvant therapy after resection of T1 N1 M0 and T2 N1 M0 non-small cell lung cancer. J Thorac Cardiovasc Surg. 1986; 91 344-349
- 21 Marks L B, Prosnitz L R. Postoperative radiotherapy for lung cancer: the breast cancer story all over again?. Int J Radiat Oncol Biol Phys. 2000; 48 625-627
- 22 Sawyer T E, Bonner J A, Gould P M. et al . Factors predicting patterns of recurrence after resection of N1 non-small cell lung carcinoma. Ann Thorac Surg. 1999; 68 1171-1176
- 23 Wagner H. Postoperative adjuvant therapy for patients with resected non-small cell lung cancer: still controversial after all these years. Chest. 2000; 117 110S-118S
- 24 Bunn P A, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer. A time for reassessment?. Chest. 2000; 117 119S-122S
- 25 Strauss G M. Role of chemotherapy in stages I to III non-small cell lung cancer. Chest. 1999; 116 509S-516S
- 26 Non-small Cell Lung Cancer Collaborative Group . Chemotherapy in non-small cell lung cancer: meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ. 1995; 311 899-909
- 27 Rosell R, Gomez-Codina J, Camps C. et al . A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994; 330 153-158
- 28 Roth J A, Fossella F, Komaki R. et al . A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994; 86 673-680
- 29 Eberhardt W, Wilke H, Stamatis G. et al . Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small cell lung cancer: mature results of a phase II trial. J Clin Oncol. 1998; 16 622-634
- 30 Stamatis G, Eberhardt W, Stüben G. et al . Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg. 1999; 68 1144-1149
- 31 Pisters K M, Ginsberg R J, Giroux D J. et al . Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg. 2000; 119 429-439
Dr. med. A. Marra
Abteilung für Thoraxchirurgie und thorakale Endoskopie, Ruhrlandklinik
Tüschener Weg 40
45239 Essen